Are you Dr. Crombez?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10833 Le Conte Ave
12-441 Mdcc
Los Angeles, CA 90095Phone+1 310-206-3952Fax+1 310-206-0209
Summary
- Dr. Eric Crombez, MD is a medical geneticist in Los Angeles, California.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 2000 - 2005
Wayne State University School of MedicineClass of 2000
Clinical Trials
- Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase Start of enrollment: 2007 Jul 25
- Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD) Start of enrollment: 2012 Feb 02
Publications & Presentations
PubMed
- 33 citationsClinical and molecular heterogeneity in patients with the cblD inborn error of cobalamin metabolism.Isabelle R. Miousse, David Watkins, David Coelho, Tony Rupar, Eric Crombez
The Journal of Pediatrics. 2009-04-01 - 130 citationsThe response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II,...Barbara K. Burton, Dorothy K. Grange, Andrzej Milanowski, G. Vockley, François Feillet
Journal of Inherited Metabolic Disease. 2007-09-12 - 92 citationsHyperargininemia due to liver arginase deficiency.Eric Crombez, Stephen D. Cederbaum
Molecular Genetics and Metabolism. 2005-03-01
Press Mentions
Gene Therapy Redosing Gains Traction as Need Grows and Novel Strategies EmergeOctober 20th, 2021- Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy ProgramApril 22nd, 2021
- Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson DiseaseDecember 9th, 2020
- Join now to see all
